Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like I*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000287	Insmed Incorporated	03/18/2025	71558059028	Arikayce (Amikacin) Inhalation Suspension 590 MG/8.4ML 28 Kits	01/01/2025	765.43	16073.94	05/15/2035	Single Source Drug	None	None	254800000	None	Response to current economic circumstances	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000084	Ipsen Biopharmaceuticals, Inc.	02/14/2025	72607010000	Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets).	02/15/2025	605.00	20775.00	05/03/2038	Single Source Drug	None	None	None	1	None	1	None	1	08/12/2022	Epizyme, Inc.	None	None	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased Epizyme, Inc. in August 2022, including Tazverik. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of Epizyme, Inc. is available on p. 82, Note 1.2 of section 3.2.5 of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2023/04/06183729/EN_UNIVERSAL-REGISTRATION-DOCUMENT-2022-BD.pdf	17746.00	16585.00	2020	15500.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.